Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 29;39(45):6573-6584.
doi: 10.1016/j.vaccine.2021.08.010. Epub 2021 Sep 30.

A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future

Collaborators, Affiliations
Free article
Review

A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future

Kristine A Moore et al. Vaccine. .
Free article

Abstract

Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.

Keywords: Broadly protective influenza vaccines; Influenza; Pandemic preparedness; Roadmap; Seasonal influenza vaccines; Universal influenza vaccines.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Kristine Moore, Julia Ostrowsky, Angela Mehr, Michael Osterholm report financial support was provided by Wellcome Trust. Kristine Moore, Michael Osterholm report a relationship with Wellcome Trust that includes: funding grants. Coauthor received grants to the organization from Sanofi Pasteur, received grants from US CDC, PATH, Wellcome Trust, South African MRC. (CC) Coauthor is a former Director of one of the WHO International Reference Centres for influenza and was part of the biannual strain selection group. His family superannuation fund holds some shares in companies which produce vaccines, including Influenza vaccine (Pfizer, Merck and CSL) and specific antiviral agents (Vaxart). (IG) Coauthor is an independent Director of two organisations that support vaccine development, the Coalition for Epidemic Preparedness Innovations and MSD Wellcome Trust Hilleman Laboratories Pvt; Ltd. Neither is working on influenza vaccines. (GK) Coauthor has the following declarations: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to universal influenza virus vaccines, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. I would also like to note the following, which could be perceived as a conflict of interest: I have previously published work on influenza virus vaccines with S. Gilbert (University of Oxford); have consulted for Curevac, Merck and Pfizer (before 2020); I am currently consulting for Pfizer, Seqirus and Avimex; my laboratory is collaborating with Pfizer on animal models of SARS-CoV-2 and with Dynavax on influenza virus vaccines; my laboratory is collaborating with N. Pardi at the University of Pennsylvania on mRNA vaccines against SARS-CoV-2 and my laboratory was working in the past with GlaxoSmithKline on the development of influenza virus vaccines and two of my mentees have recently joined Moderna. (FK)].

Similar articles

Cited by

Publication types

Substances

LinkOut - more resources